Hepatocellular carcinoma
CHRSCoherus BioSciences Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Casdozokitug (casdozo) combination in Hepatocellular carcinoma. The expected timing is based on the latest available company guidance and may change.
1/18/24- Positive Ph2 data at ASCO GI '24. 1/22/25- Presented final Ph2 data of casdozo + atezolizumab/bevacizumab combo at ASCO-GI '25. Data demonstrated durability of response. Initiated new Ph2 study evaluating casdozo + bev and tori. 11/06/25:- Cytokines 2025 biomarker data in HCC; Ph2 randomized casdozokitug/toripalimab/bevacizumab first readout expected Mid-2026. 03/09/26:- ASCO GI 2025 combo data showed 38% ORR, 17% CR; randomized Ph2 first readout still expected Mid-2026. 05/11/26:- Randomized Ph2 1L uHCC casdozokitug/toripalimab/bevacizumab study fully enrolled; first data readout still expected Mid-2026. 08/05/26:- Casdozokitug uHCC enrollment complete; first data expected October 2026.
Verification
Confirm timing and program details against the company announcement or filing.